Current Portfolio Companies
Apexian Pharmaceuticals, Inc.
Apexian Pharmaceuticals is an emerging clinical stage biotechnology company founded on the scientific discoveries of Dr. Mark R. Kelley, whose groundbreaking work on APE1/Ref-1 redox protein signaling at the Indiana University School of Medicine has provided unique insight into this important biological target. Dr. Kelley’s research, and the research of other scientists worldwide, has shown that inhibitors of APE1/Ref-1 redox signaling affect numerous transcription factors involved in cancer cell signaling and survival.
Previously Managed Portfolio Companies
BioVigilant Systems, Inc.
BioVigilant Systems, Inc. develops microbial detection technology for the environmental monitoring needs of pharmaceutical, biotechnology, and healthcare markets. It offers IMD-A, which are instantaneous microbial detection systems for environmental air monitoring for microbial contamination; IMD-W System, a system for pharmaceutical grade waters for assessing and reacting to bioburden risks in real time; and PharmaMaster, a software that is designed for measurement setup, monitoring, and analysis.
Acquired by Yamatake, Inc.
CoLucid Pharmaceuticals, Inc.
CoLucid was a biotech company focusing on therapies for CNS disorders, Migraine, sleep/wake disorders, chronic pain, Alzheimer’s disease, and psychiatric disorders.
Acquired by Eli Lilly and Company, Inc.
Grand River Aseptic Manufacturing, Inc.
Grand River Aseptic Manufacturing (GRAM) is a full-service parenteral contract manufacturer, approved by the FDA for aseptic manufacturing, with and without terminal sterilization. The Company has two facilities in downtown Grand Rapids, Michigan. The Company serves projects from pre-clinical trials through successful commercialism and can assist with pharmaceutical development, manufacturing, analytical testing and regulatory support.
Majority purchase by Arlington Capital Partners.
Intelligent Delivery Systems (FlowCo, Inc.)
Muroplex Therapeutics, Inc.
The company was advancing a proprietary approach for immunomodulatory therapy. This novel approach is based upon synthetic ligands for the TLR2 receptor. The established role of TLR2 in a wide range of inflammatory and autoimmune diseases makes this target particularly attractive. Muroplex TLR2 ligands have the potential to become breakthrough therapies for significant unmet medical needs related to inappropriate immune response. The compound candidate was in preclinical development.
Closed Operations.
Serenex Pharmaceuticals, Inc.
Serenex developed a small molecule Hsp90 inhibitors using a proprietary high–content screening platform that enabled the company to rapidly and simultaneously optimize libraries of compounds against a multitude of important therapeutic and toxicity targets. This novel technology improved the overall efficiency across the entire spectrum of drug discovery by dramatically improving library screening, mechanism of action determination and toxicity testing, lead optimization and candidate selection.
Acquired by Pfizer, Inc.
Apexian Pharmaceuticals, Inc.
Apexian Pharmaceuticals is an emerging clinical stage biotechnology company founded on the scientific discoveries of Dr. Mark R. Kelley, whose groundbreaking work on APE1/Ref-1 redox protein signaling at the Indiana University School of Medicine has provided unique insight into this important biological target. Dr. Kelley’s research, and the research of other scientists worldwide, has shown that inhibitors of APE1/Ref-1 redox signaling affect numerous transcription factors involved in cancer cell signaling and survival.
Previously Managed Portfolio Companies
BioVigilant Systems, Inc.
BioVigilant Systems, Inc. develops microbial detection technology for the environmental monitoring needs of pharmaceutical, biotechnology, and healthcare markets. It offers IMD-A, which are instantaneous microbial detection systems for environmental air monitoring for microbial contamination; IMD-W System, a system for pharmaceutical grade waters for assessing and reacting to bioburden risks in real time; and PharmaMaster, a software that is designed for measurement setup, monitoring, and analysis.
Acquired by Yamatake, Inc.
CoLucid Pharmaceuticals, Inc.
CoLucid was a biotech company focusing on therapies for CNS disorders, Migraine, sleep/wake disorders, chronic pain, Alzheimer’s disease, and psychiatric disorders.
Acquired by Eli Lilly and Company, Inc.
Grand River Aseptic Manufacturing, Inc.
Grand River Aseptic Manufacturing (GRAM) is a full-service parenteral contract manufacturer, approved by the FDA for aseptic manufacturing, with and without terminal sterilization. The Company has two facilities in downtown Grand Rapids, Michigan. The Company serves projects from pre-clinical trials through successful commercialism and can assist with pharmaceutical development, manufacturing, analytical testing and regulatory support.
Majority purchase by Arlington Capital Partners.
Intelligent Delivery Systems (FlowCo, Inc.)
Muroplex Therapeutics, Inc.
The company was advancing a proprietary approach for immunomodulatory therapy. This novel approach is based upon synthetic ligands for the TLR2 receptor. The established role of TLR2 in a wide range of inflammatory and autoimmune diseases makes this target particularly attractive. Muroplex TLR2 ligands have the potential to become breakthrough therapies for significant unmet medical needs related to inappropriate immune response. The compound candidate was in preclinical development.
Closed Operations.
Serenex Pharmaceuticals, Inc.
Serenex developed a small molecule Hsp90 inhibitors using a proprietary high–content screening platform that enabled the company to rapidly and simultaneously optimize libraries of compounds against a multitude of important therapeutic and toxicity targets. This novel technology improved the overall efficiency across the entire spectrum of drug discovery by dramatically improving library screening, mechanism of action determination and toxicity testing, lead optimization and candidate selection.
Acquired by Pfizer, Inc.